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Abstract
 
Many tumor-associated antigens are derived from nonmutated “self” proteins. T cells infiltrat-
ing tumor deposits recognize self-antigens presented by tumor cells and can be expanded in
vivo with vaccination. These T cells exist in a functionally tolerant state, as they rarely result in
tumor eradication. We found that tumor growth and lethality were unchanged in mice even
after adoptive transfer of large numbers of T cells specific for an MHC class I–restricted epitope
of the self/tumor antigen gp100. We sought to develop new strategies that would reverse the
functionally tolerant state of self/tumor antigen-reactive T cells and enable the destruction of
large (with products of perpendicular diameters of 
 
 
 
50 mm
 
2
 
), subcutaneous, unmanipulated,
poorly immunogenic B16 tumors that were established for up to 14 d before the start of treat-
ment. We have defined three elements that are all strictly necessary to induce tumor regression
in this model: (a) adoptive transfer of tumor-specific T cells; (b) T cell stimulation through an-
tigen-specific vaccination with an altered peptide ligand, rather than the native self-peptide;
and (c) coadministration of a T cell growth and activation factor. Cells, vaccination, or cyto-
kine given alone or any two in combination were insufficient to induce tumor destruction.
Autoimmune vitiligo was observed in mice cured of their disease. These findings illustrate that
adoptive transfer of T cells and IL-2 can augment the function of a cancer vaccine. Further-
more, these data represent the first demonstration of complete cures of large, established,
poorly immunogenic, unmanipulated solid tumors using T cells specific for a true self/tumor
antigen and form the basis for a new approach to the treatment of patients with cancer.
Key words: adoptive cell transfer • immunotherapy • IL-2 • recombinant poxvirus • T cell 
epitope
 
Introduction
 
The observation that many tumor-associated antigens are
nonmutated “self-antigens” has raised the question of
how to induce large numbers of highly active, self/tumor
antigen-specific T cells capable of destroying large, estab-
lished tumors. Nonmutated self-antigens are particularly
attractive targets for immunotherapy, because they are
shared among patients, obviating the need for personal-
ized vaccine development (1–6). We and others have at-
tempted numerous vaccination approaches targeting self/
tumor antigens. However, despite the increased numbers
of self/tumor antigen-specific T cells, the reproducible
induction of significant destruction of large, established
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cancers in mouse or in man using any self-antigen vac-
cine-based approach remains an elusive goal (7–9). A state
of functional tolerance apparently exists in the tumor-
bearing host.
This state of functional tolerance, defined here as the co-
existence of tumor-specific T cells and growing tumor
cells, may be incomplete. There is evidence indicating that
antigen expression by tumors leads to limited T cell activa-
tion without tumor regression (10–12). Work in the spon-
taneous insulinoma model has indicated that effector “ex-
haustion,” rather than tumor escape is the underlying
mechanism of functional tolerance (13). Work using other
antigenic systems indicates that antigens expressed by tu-
mors actively tolerize tumor-specific T cells (14). Antigenic
“ignorance” to tumors has also been proposed as a mecha-
nism for functional tolerance (15). Thus, the mechanisms
underlying the observed functional tolerance of antitumor
T cells remain unclear.
The modeling of self-reactivity is likely to be important
in the development of new immunotherapies that target
self/tumor antigens, but many of the currently available tu-
mor models that model the complete destruction of estab-
lished tumors target “foreign” antigens. The antigenic sys-
tems most commonly used until now by us and others
include chicken egg ovalbumin, 
 
 
 
-galactosidase from 
 
Esch-
erichia coli
 
, the L
 
d
 
 major histocompatibility antigen, and
hemagglutinin or nucleoprotein derived from influenza A vi-
rus (14, 16–20). These models have shed valuable light on
basic immunologic principles (21), but it is unclear to what
extent the results obtained from these models reflect im-
mune responses against true self/tumor antigens. For exam-
ple, the high levels of expression of foreign antigens under
the control of constitutively activated viral promoters may
not mimic the expression of self-antigens that are the tar-
gets of tumor-specific T cells. Most importantly, each of
these model antigens has been selected for study because
they induce unusually strong T cell responses, perhaps not
reflecting T cell responses characteristic of those observed
against tumor antigens.
We sought to study the activation and proliferation of
self-specific T cells that can infiltrate and destroy large, es-
tablished tumors. Here, we investigate parameters that can
be manipulated in vivo to transform a completely ineffec-
tive antitumor response into a productive one. To utilize a
tumor model that is more physiologically relevant, we used
the poorly immunogenic B16 melanoma, a highly aggres-
sive tumor in C57BL/6 mice (22). A much-studied tumor,
B16 expresses no MHC class II and very low levels of
MHC class I, although both are inducible upon treatment
with interferon-
 
 
 
 (23). The B16 melanoma expresses the
mouse homologue (pmel-17) of human gp100, an enzyme
involved in pigment synthesis that is expressed by the ma-
jority of malignant melanoma cells, as well as by normal
melanocytes. gp100 is a member of a family of “self” (i.e.,
unmutated), melanoma/melanocyte differentiation antigens
that are widely expressed by melanoma cells. These anti-
gens are frequently the targets of T cells that infiltrate hu-
man tumors (24).
The generation of autoreactive T cells in vivo may be
difficult because of the mechanisms of central and periph-
eral tolerance and the impact of antigen expression by tu-
mor tissue on T cell function (14, 25–27). Altered peptide
ligands have been used to improve the reactivity of T
cells specific for self/tumor antigens in mouse and man (9,
28–30). For gp100, H-2D
 
b
 
-restricted CD8
 
 
 
 T cells ca-
pable of recognizing B16 melanoma and normal melano-
cytes could only be elicited when the altered peptide was
used (31). We described previously the cloning of the un-
mutated mouse homologue of gp100 (mgp100) from B16
melanoma (32). We have also described the identification
of a peptide derived from human (h)gp100, KVPRN-
QDWL (hgp100
 
25–33
 
), that represents an altered peptide
ligand form of mgp100
 
25–33
 
, EGSRNQDWL (31). Upon
establishing this model for vaccination against self/tumor
antigen, our next goal was to identify immunotherapeutic
strategies that would induce the regression of large estab-
lished tumors using CD8
 
 
 
 T cells specific for a self-antigen.
 
Materials and Methods
 
Generation of Pmel-1 TCR Transgenic Mice. 
 
To study self/tu-
mor antigen-specific T cell responses to melanoma, we developed
a transgenic mouse strain on a C57BL/6 background and named
it pmel-1. RNA was isolated from clone 9, a gp100
 
25–33
 
-specific,
H-2D
 
b
 
–restricted CD8
 
 
 
 T cell clone (31), and 
 
 
 
 and 
 
 
 
 TCR re-
gions were amplified by 5
 
 
 
-Rapid Amplification of cDNA Ends
(5
 
 
 
-RACE, Life Technologies) using constant region anti-sense
primers 
 
 
 
1 (5
 
 
 
-GGCTACTTTCAGCAGGAGGA-3
 
 
 
) and 
 
 
 
1
(5
 
 
 
-AGGCCTCTGCACTGATGTTC-3
 
 
 
), respectively. 5
 
 
 
-
RACE products were amplified with nested TCR 
 
 
 
 and 
 
 
 
 con-
stant region primers 
 
 
 
2 (5
 
 
 
-GGGAGTCAAAGTCGGTGAAC-
3
 
 
 
) and 
 
 
 
2 (5
 
 
 
-CCACGTGGTCAGGGAAGAAG-3
 
 
 
), and
cloned into pCR4TOPO TA sequencing vectors (Invitrogen).
TCR 
 
 
 
 and 
 
 
 
 transcripts were sequenced as V
 
 
 
1/J
 
 
 
TA19/C
 
 
 
and V
 
 
 
13S1/D
 
 
 
1/J
 
 
 
1S6/C
 
 
 
1. Genomic cloning PCR primers
were designed based on the method described previously by
Kouskoff et al. (33). The 
 
 
 
 and 
 
 
 
 genomic variable domains were
PCR amplified (Perkin-Elmer) with primers g
 
 
 
1 (5
 
 
 
-TCTC-
CCGGGCTTCTCACTGCCTAGCCATGATGAAATCCT-
TGAGTGTTTC-3
 
 
 
) and g
 
 
 
2 (5
 
 
 
-GTAGCGGCCGCGTAAA-
ATCTATCCTAGTGTTCCCCAGA-3
 
 
 
) or g
 
 
 
1 (5
 
 
 
-GATCT-
CGAGAATCTGCCATGGGCACCAG-3
 
 
 
) and g
 
 
 
2 (5
 
 
 
-GAT-
ACCGCGGTTCCTTTCCAAGACCAT-3
 
 
 
), respectively. The
genomic variable domains were TA-cloned into pCR4TOPO
(Invitrogen), validated by sequencing, subcloned into TCR cas-
sette vectors provided by Dr. D. Mathis (Harvard Medical School,
Boston, MA; reference 33), and co-injected into fertilized C57BL/6
embryos (Science Applications International Corporation) yield-
ing three TCR transgenic founder lines. Unpublished transgenic
mice expressing the 
 
 
 
 
 
/
 
 
 
 
 
 transgenic TCR with specificity for a
K
 
b
 
-restricted epitope from 
 
 
 
-galactosidase (34) were identically
constructed in our laboratory and were used as controls in some
experiments.
 
Mice and Tumor Cells. 
 
C57BL/6 and pmel-1 TCR trans-
genic mice were bred and housed at the National Institutes of
Health (NIH) and Netherlands Cancer Institute animal facilities.
Rag-1
 
 
 
/
 
 
 
 mice were obtained from Jackson ImmunoResearch
Laboratories. B16 (H-2
 
b
 
) is a gp100
 
 
 
 spontaneous murine mela-
noma obtained from the National Cancer Institute tumor reposi-T
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tory and maintained in culture media (CM) comprised of RPMI
1640 with 10% heat-inactivated fetal bovine serum (Biofluids),
0.03% 
 
l
 
-glutamine, 100 
 
 
 
g/ml streptomycin, 100 
 
 
 
g/ml penicil-
lin, and 50 
 
 
 
g/ml gentamicin sulfate (NIH Media Center).
 
Peptides and Recombinant Poxviruses. 
 
All synthetic peptides
were synthesized using regular F-MOC chemistry. The syn-
thetic, H-2D
 
b
 
–restricted peptides hgp100
 
25–33
 
, KVPRNQDWL,
mgp100
 
25–33
 
, EGSRNQDWL, and NP
 
366–374
 
, ASNENMETM,
were synthesized by Peptide Technologies to a purity 
 
 
 
99% by
HPLC and amino acid analysis. All recombinant vaccinia viruses
(rVVs) and recombinant fowlpox viruses (rFPVs) used in this pa-
per have been described previously (31) and were either generated
in our laboratory or provided by D. Panicali, L. Gritz, and A. Go-
mez-Yafal (Therion Biologics, Cambridge, MA). These viruses
were constructed and purified as described by Earl et al. (35).
 
In Vitro Activation of Pmel-1 T Cells and Cytokine Release As-
say. 
 
Peripheral blood mononuclear cells or splenocytes from
mice were depleted of erythrocytes by hypotonic lysis, cultured
in CM with 30 IU/ml rhIL-2 in the presence of 1 
 
 
 
M hgp100
 
25–33
 
peptide, and used on days 5–10 after start of the culture. For
cytokine release assays, 10
 
5 
 
T cells were cocultured in CM with
10
 
5
 
 target cells or 1 
 
 
 
M of the indicated peptide. Supernatants
were collected after 24 h and tested using an mIFN-
 
 
 
 ELISA kit
(Endogen) according to the manufacturer’s protocol.
 
Histology. 
 
Skin and tumor samples were analyzed as de-
scribed previously (36). In brief, 4-
 
 
 
m cryostat sections were
air-dried overnight and fixed in acetone for 10 min at room
temperature, preincubated in 5% (vol/vol) normal goat serum
(Central Laboratory of the Netherlands Red Cross Blood Trans-
fusion Service) and stained with 0.5 
 
 
 
g/ml anti–mouse v
 
 
 
13
mAb-FITC or mIgG1-FITC control Ab (BD Biosciences) in
PBS/1% BSA followed by rabbit anti-FITC (1:40,000; DakoCy-
tomation), biotinylated goat anti–rabbit antibody (1:400; Dako-
Cytomation) and streptavidin–biotin-conjugated alkaline phos-
phatase complex (1:100, ABC-protocol; DakoCytomation).
Color was developed using Permanent red chromogen substrate
(PRC kit; Cell Marque Corporation) and sections were counter-
stained with hematoxylin.
 
Flow Cytometry and Intracellular IFN-
 
 
 
 Assay. 
 
To obtain ap-
propriate lymphocyte samples, mice were either tail-bled on indi-
cated days after vaccination or killed and splenectomized for fresh
splenocytes. Where designated, splenocytes were cultured as de-
scribed previously (31). Erythrocytes were removed by hypotonic
lysis or ficoll gradient separation, and cells were stained with the
indicated dilutions of mAbs against CD8a (1:20, clone 53–6.7),
CD4 (1:10, clone H129.19), V
 
 
 
13 (1:10, clone MR12–3), CD25
(1:10, clone PC61), CD44 (1:10, clone IM7), CD62L (1:10,
clone MEL-14), and CD69 (1:10, clone H1.2F3). All antibodies
were purchased from BD Biosciences. H2-D
 
b
 
–mgp100
 
25–33
 
 tetra-
mers were a gift from M. Toebes and T.N.M. Schumacher
(Netherlands Cancer Institute, Amsterdam, Netherlands). Propid-
ium iodide staining cells were excluded from analysis. Intracellu-
lar IFN-
 
 
 
 assay was performed using the Cytofix/Cytoperm kit
(BD Biosciences) according to the manufacturer’s recommenda-
tions. Samples were analyzed using a FACScalibur™ flow cytom-
eter and CELLquest™ software.
 
Adoptive Transfer and Tumor Treatment. 
 
Mice were injected
subcutaneously with 1–5   105 B16 melanoma cells and treated
with intravenous adoptive transfer of freshly isolated 106–7 fresh
splenocytes ( 2   106 CD8  V 13  T cells) or in vitro–acti-
vated pmel-1 splenocytes (106–7 CD8  V 13  T cells). Mice (n  
5 for all groups) were vaccinated by intravenous injection of 2  
107 plaque-forming units of rVV or rFPV encoding mgp100,
hgp100, or  -galactosidase (31) or by subcutaneous injection
with 100  l water/IFA emulsion containing 100  g of
mgp10025–33, hgp10025–33, or  -gal96–103 peptide followed by two
daily intraperitoneal injections of 100  g anti-CD40 mAb puri-
fied from FGK45 hybridoma culture supernatant. rhIL-2 (a gift
from Chiron Corp.) was administered intraperitoneally directly
after vaccination (100,000 Cetus Units or 600,000 IU rhIL-2 in
PBS, twice daily for 3–5 d). Tumors were measured with calipers
and the products of perpendicular diameters were recorded. Mice
were killed once tumors reached 400 mm2. All experiments were
performed in a blinded, randomized fashion (measuring investiga-
tor had no knowledge of the experimental group) and performed
independently at least twice with similar results.
Results
Despite Large Numbers of gp100-specific T Cells, B16 Mela-
noma Grows Normally in Pmel-1 TCR Transgenic Mice.  To
study self/tumor antigen-specific T cell responses to mela-
noma, we developed a transgenic mouse strain on a
C57BL/6 background and named it pmel-1. Pmel-1 trans-
genic mice expressed the V 1V 13 TCR from a cloned T
cell (clone 9) described previously (31). Clone 9, like the
pmel-1 TCR transgenic cells derived from it, recognized
an H-2Db–restricted epitope corresponding to amino acids
25–33 of gp100. Virtually all ( 95%) of the CD8  T cells
in pmel-1 TCR transgenic mice were V 13 , amounting
to  20% of all splenocytes (Fig. 1 A). Pmel-1 T cells in
blood and spleen generally expressed baseline levels of the
activation/effector markers CD25, CD44, and CD69, indi-
cating that most of the transgenic cells were in the naive
state. The CD62L levels were as high if not higher than
those found in normal splenocytes, which was also consis-
tent with the finding that pmel-1 cells were largely naive.
Upon in vitro stimulation with 1  M of the hgp10025–33
peptide, T cells from pmel-1 TCR transgenic mice prolif-
erated extensively and developed an effector phenotype
that included the up-regulation of CD25, CD44, and
CD69 and the partial down-regulation of CD62L (Fig. 1
A). Functionally, pmel-1 T cells released IFN-  after stim-
ulation with mgp100, hgp100 peptide (Fig. 1 B), or B16
melanoma cells, which are naturally mgp100  (Fig. 1 C).
The transgenic T cells resembled the reactivity of the origi-
nal clone 9, from which their  /  TCR was cloned (Fig. 1
C and not depicted). Thus, the pmel-1 transgenic mouse
could be used as a source of naive T cells with specificity
for the gp10025–33 epitope.
To determine the role of T cell precursor frequency in
the ability of the immune system to reject tumors, we in-
jected B16 tumor cells subcutaneously into pmel-1 TCR
transgenic mice and nontransgenic littermates. Surprisingly,
tumors grew at the same rate in pmel-1 mice despite the
presence of overwhelming numbers of CD8  gp100-spe-
cific T cells (Fig. 1 D). Likewise, the adoptive transfer of
naive or in vitro–activated gp100-specific pmel-1 spleno-
cytes into tumor-bearing mice alone or in combination
with IL-2 had minimal effects on tumor growth or the sur-
vival of tumor-bearing mice. Thus, the mere presence of
naive or activated tumor-specific T cells alone was insuffi-T
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cient to cause the regression of the subcutaneous tumor,
thereby indicating that the pmel-1 cells were functionally
tolerant to the tumor.
Immunization with Altered Peptide Ligand Results in Higher
Numbers of Self/Tumor Antigen-Specific T Cells That Have
Limited Antitumor Efficacy.  In an effort to break the func-
tionally tolerant state of pmel-1 cells, we immunized tu-
mor-bearing wild-type C57BL/6 mice with rVVs or rFPVs,
encoding either the self-antigen, mgp100, or the altered
ligand, hgp100 (31). To track the activation and antitumor
activity of naive pmel-1 T cells in vivo, we adoptively
transferred pmel-1 splenocytes into otherwise normal, un-
manipulated mice bearing subcutaneous B16 tumors estab-
lished for 3 d. Vaccination with rVVmgp100 did not cause
any significant antitumor effect. However, vaccination
with rVVhgp100 induced a modest delay in subcutaneous
tumor growth in some experiments, one of which is shown
(Fig. 2 A).
FACS® analysis using mgp100-specific MHC class I tet-
ramers showed that vaccination with rVVmgp100 induced
a weak and sometimes undetectable T cell response,
whereas use of rVVhgp100 markedly increased specific T
cell numbers (Fig. 2 B). Similar results were obtained when
we used a “minigene” rVV encoding the nine amino acid
minimal peptide determinant preceded by an ER-insertion
sequence (31; unpublished data), or when we used the syn-
thetic 9-mer peptides emulsified in IFA and given with
anti-CD40 antibody (37). Only immunization with the
hgp10025–33 effectively induced gp100-specific T cells, and
these T cell responses were cross-reactive with mgp10025–33.
These findings confirmed earlier observations that gp100
sequences outside the minimal determinant do not contrib-
ute to the differential immunogenicity of rVVmgp100 and
rVVhgp100 (31).
Both hgp10025–33 and mgp10025–33 peptides contain the
optimal MHC anchor residues at the dominant anchor po-
Figure 1. Despite large numbers of gp100-specific T cells, B16 melanoma grows normally in pmel-1 TCR transgenic mice. (A) Generation and char-
acterization of pmel-1 TCR transgenic mice. Single cell suspensions of spleens from a 6-wk-old pmel-1 mouse and a nontransgenic C57BL/6 mouse lit-
termate as well as pmel-1 splenocytes cultured with hgp10025–33 peptide were stained for CD8, V 13, and the activation markers CD25, CD44, CD62L,
and CD69, and analyzed by FACS®. (B) Recognition of gp100 peptide by pmel-1 T cells. PBL from pmel-1 “D8” founder were cultured for 7 d with
mgp10025–33 peptide, washed, and incubated with titrated doses of mgp10025–33 (native) or hgp10025–33 (altered) peptide. IFN-  production was measured
by ELISA on culture supernatants. (C) Pmel-1 T cells specifically recognize B16 melanoma. Cultured pmel-1 splenocytes (gray bars) or clone 9 (black
bars) were coincubated with B16 melanoma, EL-4 thymoma, MCA207 sarcoma, MC38 colon carcinoma cells, or CM. Supernatants were assessed for
IFN-  production by ELISA. (D) B16 melanoma grows progressively in pmel-1 TCR transgenic mice. B16 cells were implanted in 6-wk-old pmel-1 T
cell receptor transgenic mice and littermates not expressing the transgene. All experiments shown were performed independently at least two times with
similar results.T
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sitions, 5 (N) and 9 (L). However, the difference in the
three amino-terminal residues resulted in T cell recognition
at  100-fold lower concentrations of the hgp10025–33 pep-
tide when compared with mgp10025–33 (Fig. 1 B). We have
assessed previously the binding efficiency of the peptides
for the H-2 Db class I molecule, finding that the human
peptide bound to H-2 Db with 100-fold greater efficiency
than the mouse peptide (31). Here, we extended these ob-
servations by evaluating the dissociation time of peptide
from MHC I molecules on RMA-S cells, again observing
significantly decreased binding at time zero of mgp10025–33,
compared with hgp10025–33, followed by an accelerated dis-
sociation time for the mgp10025–33 peptide (Fig. 2 C).
Together, these results suggest that pmel-1 T cells can
escape central and peripheral tolerance and are not com-
pletely refractory to stimulation by self-antigen because the
immunogen encoding the altered peptide ligand activated
and expanded these self-reactive T cells and conferred lim-
ited antitumor efficacy.
Stimulation of Adoptively Transferred T Cells through Anti-
gen-specific Vaccination and IL-2 Causes Regression and Long-
term Cures of Large Established Tumors.  Enhanced activation
of adoptively transferred pmel-1 T cells by immunization
with an altered peptide ligand resulted in inconsistent and
limited antitumor effects, leading to growth retardation but
not regression of small tumors. Therefore, we set out to
determine other factors that might enhance self-specific T
cell activation and antitumor effect. We have explored pre-
viously the uses of a variety of T cell costimulatory,
growth, and activation factors and found that in mouse
models, IL-2 can augment the function of recombinant vi-
rus–based vaccines (38). To determine if we could enhance
the activation of antitumor T cells in a way that would en-
able them to treat large, established, vascularized tumors,
we adoptively transferred pmel-1 splenocytes into mice
bearing subcutaneous B16 tumors established for 7 (Fig. 3,
A and B) or 14 d (Fig. 3, C and D). This adoptive transfer
was followed by vaccination with rFPV encoding the
hgp100-altered peptide ligand and administration of IL-2.
This combined treatment reproducibly induced tumor re-
gression and even long-term cures of mice bearing estab-
lished tumors larger than 50 mm2 (Fig. 3 C).
Invariably, as observed in  20 independently performed
experiments, the combination of adoptive transfer of self/
tumor-specific CD8  T cells, antigenic stimulation with an
altered peptide ligand, and administration of IL-2 was re-
quired to induce this strong antitumor effect. The regimen
Figure 2. Enhanced T cell and antitumor response by adoptively trans-
ferred T cells after vaccination with altered peptide ligand. (A) Enhanced
antitumor efficacy upon vaccination with rVV encoding altered peptide
ligand. Tumor growth was measured in C57BL/6 mice bearing 3-d B16
tumors that received pmel-1 splenocytes followed immediately by vacci-
nation with rVVLacZ, rVVmgp100, rVVhgp100, or no treatment. (B)
Increased numbers of pmel-1 T cells from mice immunized with rVV en-
coding altered peptide ligand. Lymphocytes from mice described in A
were isolated from peripheral blood and stained for CD8 and V 13 be-
fore FACS® analysis. Numbers of CD8 Tm  cells are depicted through
time as percentage of total CD8  cells. (C) Prolonged peptide/MHC dis-
sociation time of altered peptide ligand. RMA-S cells were incubated
with hgp10025–33 (closed symbols) or mgp10025–33 (open symbols, shown
at corresponding concentrations) at 25 C overnight. The cells were
washed three times, incubated at 37 C for the time designated, and added
to 7-d cultured pmel-1 T cells for 24 h. IFN-  in culture supernatants
was quantified by ELISA. Experiments were performed independently at
least twice with similar results.T
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is ineffective against tumors that are gp100-negative (un-
published data). Administration of either pmel-1 cells
alone, IL-2 alone, vaccine alone, or any combination of
just two of the three of these immunotherapeutic compo-
nents induced weak, if any, antitumor effects (Fig. 3, A and
B). In an effort to use the model in a clinically relevant
way, we have focused on the adoptive transfer of T cells.
However, in mice transgenic for the pmel-1 TCR, IL-2
given in combination with vaccination using the altered
form of gp100 was also therapeutically effective in the treat-
ment of established B16 tumors (unpublished data).
T cells derived from fresh, naive splenocytes, or from cul-
tured splenocytes activated ex vivo, could mediate the regres-
sion of large, established, subcutaneous tumors in vivo. All
mice in Fig. 4 A that were treated with the combined regi-
men of adoptive transfer of pmel-1 cells (either with fresh or
cultured T cells), IL-2, and vaccination with rFPVhgp100
were complete and long-term responders. These responses
have been followed for  1 yr, and are often accompanied by
the development of limited vitiligo, which generally begins at
the site of tumor regression, and then spreads in an unpredict-
able pattern throughout the mouse. Vitiligo is not observed
when mice are treated with control  -galactosidase–specific
T cells (unpublished data). A representative cohort of com-
plete responder mice observed  1 yr after treatment corre-
sponds to the group treated with cultured T cells, IL-2, and
vaccination with rFPVhgp100, shown in Fig. 4 B.
It is important to note that complete cures of tumors are
not always observed when using the triple combination of
cells, vaccine, and cytokine, especially when doses of indi-
vidual components are reduced (unpublished data). Thus, it
may be useful to elucidate the minimal optimal treatment
protocol required to reproducibly induce the regression of
large B16 tumors established for 14 d. 105 Cetus units (6  
105 IU) twice a day for 3 d was clearly sufficient when
given in combination with 107 fresh or cultured pmel-1
cells and 2   107 plaque-forming units of rFPVhgp100 to
reproducibly induce the regression of large B16 tumors es-
tablished for 14 d. We used adoptively transferred cells in
an effort to model a clinical possibility, but as mentioned
earlier, vaccination plus IL-2 is effective in pmel-1 TCR
transgenic mice bearing established tumors.
Figure 3. Adoptive transfer of tumor-specific T cells combined with vaccination and IL-2 causes regression and cure of large, established tumors. B16
tumor was implanted subcutaneously into C57BL/6 mice treated by adoptive transfer of fresh pmel-1 splenocytes   vaccination with rFPVhgp100 either
7 (A and B) or 14 d (C and D) after tumor inoculation. IL-2 was administered twice daily for six doses. Fresh or cultured splenocytes were effective in the
treatment of large, established tumors. Splenocytes derived from an identically constructed TCR transgenic mouse with specificity for  -galactosidase
were used as a control in some experiments (C and D) and were not therapeutic. Statistically significant tumor regression was seen in mice treated with
pmel-1 cells given in combination with rFPVhgp100 and IL-2 in  20 independently performed experiments. There were at least five mice/group in all
experiments. Mouse survival consistently correlated with tumor growth reduction.T
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The administration of a combination of cultured pmel-1
T cells, vaccination, and IL-2 was required even in the ab-
sence of endogenous host B or T lymphocytes, as demon-
strated by experiments in C57BL/6 Rag-1 /  knockout
mice bearing subcutaneous B16 tumors established for 14 d
(Fig. 5). The cultured cells that were transferred were
 98% CD8  by FACS® (unpublished data). Tumors
shown in Fig. 5 were treated with a suboptimal number
(106) of pmel-1 cells, resulting in resurgent tumor growth.
However, in experiments repeated more than five times,
antitumor effects were at least as strong (and generally
stronger) in Rag-1 /  mice as those seen in wild-type
C57BL/6 mice (unpublished data).
IL-2 Increases the Number and Function of Self-specific, Tu-
moricidal T Cells.  To further understand the mechanisms
of how the antitumor effector function of pmel-1 cells was
enhanced by IL-2, we monitored the levels of pmel-1 T
cells in the blood of mice using tetramer analysis to follow
the transferred cells after treatment. Data shown in Fig. 6
(A–C) are obtained from the same, representative experi-
ment. In this treatment model, using B16 tumors estab-
lished for 3 d, cell transfer combined with immunization
with the altered peptide ligand and IL-2 was required to
observe the maximal therapeutic effect (Fig. 6 A). In other
experiments, IL-2 could be replaced with either IL-7 or IL-
15 (unpublished data). Cells plus rVV encoding the altered
peptide ligand can induce limited destruction of small tu-
mor burden, but this treatment effect is not significant in
mice with large tumor burden (i.e., tumors established for
14 d).
We found that the effect of IL-2 on the levels of pmel-1
T cells, as a percentage of CD8  T cells or total nucleated
cells in blood, was modest (two- to fourfold, at most, com-
pared with treatment groups receiving adoptively trans-
ferred pmel-1 cells and vaccination at any given time in
multiple experiments; Fig. 6 B). When measured as either
percentage of all nucleated cells in blood or absolute num-
bers in the spleen, administration of IL-2 increased the rel-
ative number of pmel-1 T cells maximally threefold. IL-2
did not influence the induction of persistent memory T
cells that could be reactivated by booster vaccination 32 d
after priming (Fig. 6 C).
We sought to understand the impact of IL-2 administra-
tion on absolute numbers of pmel-1 T cells, and to measure
the effect it had on their localization and effector function.
We found that administration of IL-2 after adoptive trans-
fer and vaccination increased the total number of lympho-
cytes infiltrating into 300 mg of solid tumor by 1.9-fold 7 d
after vaccination (Fig. 6 D). The number of V 13 CD8 
Figure 4. Long-term ( 1 yr) survival of mice bearing large, established
B16 tumors after treatment with adoptive transfer of tumor-specific T
cells combined with vaccination and IL-2 is associated with the develop-
ment of vitiligo. C57BL/6 mice were treated with adoptive transfer of
fresh or cultured pmel-1 transgenic splenocytes 14 d after inoculation
with B16 melanoma and vaccinated with rFPVhgp100. IL-2 was adminis-
tered twice daily for six doses. Mice treated with fresh naive or cultured
transgenic T cells were cured of B16, and vitiligo was observed, which
started at the former tumor site. At  1-yr after therapy, these mice re-
main tumor-free with progressive vitiligo. To illustrate the autoimmune
vitiligo, a photograph of the cohort of 5/5 surviving mice treated with
cultured pmel-1 cells from A is shown in B.
Figure 5. Endogenous host B or T lymphocytes are not required for
the treatment of established B16 tumors. C57BL/6 Rag-1 /  knockout
mice bearing subcutaneous B16 tumors established for 14 d were treated
with 106 cultured pmel-1 cells given in combination with rFPVhgp100
and IL-2 as described previously. Similar results were obtained in five in-
dependently completed experiments.T
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T cells was increased by 3.3-fold, corresponding to the
modest increase in V 13 CD8  T cell levels in blood (Fig.
6 D). Strikingly, the number of V 13 CD8  T cells that
produced IFN-  directly ex vivo and without further stim-
ulation was increased 34-fold by IL-2 administration.
These data illustrate that in the absence of IL-2, T cells are
present at the tumor site but not fully activated. Thus, IL-2
acted primarily as a costimulatory/activation factor rather
than purely as a growth factor.
Histological analysis of B16 tumors 7 d after treatment of
7-d tumors with pmel-1 cells plus vaccination showed spe-
cific T cell infiltration but no marked tumor cell death or
tissue destruction (Fig. 7, left). By contrast, when the adop-
tive transfer of pmel-1 cells plus vaccination was followed
by administration of IL-2, we observed extensive tumor
cell death and loss of tissue integrity (Fig. 7, right). These
data show that strong vaccination by itself can induce pro-
liferation and tumor localization of antigen-specific T cells,
but that these T cells do not effectively mediate tumor de-
struction unless provided with exogenous cytokine.
Discussion
Strengths and Weaknesses of the Pmel-1 TCR Transgenic
Model.  Here, we have investigated parameters that can
be manipulated in vivo to transform a functionally tolerant
transgenic T cell into an activated one that mediates the re-
gression of large established tumors. As a tumor model, we
used the poorly immunogenic B16 melanoma. This tumor
failed to induce activation of adoptively transferred
mgp100-specific pmel-1 T cells. Reports on the treatment
of large, established tumors with systemic, rather than local
therapies, remain rare, but not unprecedented in the scien-
tific literature (39).
Most of the published mouse tumor models use preven-
tion of tumor implantation and growth as the measure of
success. When the treatment of established tumors is re-
ported, treated tumors are generally significantly smaller
than those treated in the present set of experiments. Fur-
thermore, many of the existing tumor systems target model
antigens that have been artificially inserted into the tumor
genome, whereas the majority of human tumor–associated
Figure 6. Persistence and function of gp100 reactive
T cells after adoptive transfer, vaccination, and admin-
istration of IL-2 in mice bearing subcutaneous B16 tu-
mors. (A–C) Data derived from the same, repre-
sentative experiment. (A) Representative treatment
experiment using C57BL/6 mice bearing B16 tumors
established for 3 d were treated with fresh pmel-1 T
cells plus vaccination with rVVLacZ, rVVmgp100, or
rVVhgp100 with or without IL-2. (B) Vaccine-induced
specific T cells in peripheral blood. Numbers of CD8 
Tm  cells isolated from PBL of groups from A are de-
picted as percentage of total CD8  cells. (C) Effect of
boost with vaccine and IL-2. Mice surviving to day 30
(continuation of B) were retreated by heterologous
boosting with rFPVhgp100 plus IL-2. Numbers of
CD8 V 13  cells isolated from blood are depicted as
percentage of total CD8  cells. (D) Effect of IL-2 on
the number and function of vaccine-induced gp100-
specific T cells in tumor tissue. The absolute numbers
used to calculate the ratios shown were obtained 7 d
after treatment (14 d after tumor implantation) and are
normalized for 300 mg of tumor tissue (the average
weight of excised tumors on day 14). These numbers
are as follows (IL-2/PBS): total lymphocyte gate
(1,758:945), CD8  T cells (1,271:619), CD8 V 13 
T cells (890:266), and CD8 V 13  IFN-   T cells
(261:8). After a 4-h restimulation with 1  M
mgp10025–33 peptide, the number of CD8 V 13 
IFN-   T cells measured from this group were (754:147)
to give a ratio of 5:1 (not depicted).T
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antigens used in current clinical efforts are nonmutated self-
antigens. In studies focusing on adoptive immunotherapy,
investigators generally report on the treatment of small pul-
monary “metastases,” which are nodules created by the in-
travenous injection of tumor cells, which are treated with
lymphocytes injected by the same route. The present paper
describes the use of large, vascularized subcutaneous tumors.
One aspect of the current model that does not model
the human tumor–bearing situation is the use of a trans-
plantable tumor rather than spontaneous melanomas aris-
ing and progressing in each mouse, which could be sub-
jected to treatment. Spontaneous tumor models can be
more cumbersome and time-consuming to work with.
However, the use of spontaneous tumors (40, 41) may
more effectively model some aspects of tumor carcinogen-
esis and treatment. Efforts to validate the findings of the
present paper in a model of spontaneous tumor are cur-
rently ongoing in the laboratory.
The Mere Presence of Tumor-reactive CD8  T Cells Is Insuf-
ficient to Induce Tumor Regression. The presence of over-
whelming numbers of mgp100-specific T cells (20% of all
splenocytes,  95% of all CD8  T cells) in pmel-1 mice did
not impact tumor growth. Apparently, large numbers of
activated tumor-specific T cells are necessary but not suffi-
cient to induce tumor destruction. This puzzling observa-
tion, observed several years ago in mice by Ohashi and col-
leagues (13), has been rediscovered in recent clinical trials
(7–9, 42).
Provision of nonspecific systemic inflammation or “dan-
ger” signals by infection of mice with control vaccinia virus
or injection of anti-CD40 mAb and IL-2 did not result in
T cell activation or suppression of tumor growth. Further-
more, in vitro–activated specific T cells neither proliferated
in response to tumor nor slowed the growth of even tiny
subcutaneous tumors. This suggests that direct presentation
of mgp100 antigen by tumor cells or its cross-presentation
by activated professional APCs is insufficient to overcome
peripheral tolerance and induce T cell activation and prolif-
eration. A possible explanation for this poor presentation
may reside in the low affinity of the mgp10025–33 peptide
for H-2 Db and the resulting brief half-life of MHC–
mgp10025–33 complexes on APCs (Fig. 2 C; references 31,
43). Indeed, vaccination with the self-antigen, mgp100, in-
duced only marginal T cell proliferation and no control of
tumor growth (Fig. 2, A and B; and Fig. 6, A and B).
When tumor-bearing recipients were vaccinated with a
peptide epitope capable of binding H-2Db with 100-fold
greater affinity than its mouse counterpart (31), we saw a
greatly increased mgp100-specific T cell response (in which
up to 80% of all CD8  T cells in the blood can be
mgp100-specific). It is possible that the use of an altered
peptide ligand is not an absolute requirement in other can-
cer vaccines, particularly if the antigenic peptide of choice
is, unlike the mgp100 peptide, highly capable of activating
T cells. However, it is likely that T cells that have survived
central and peripheral tolerance to self/tumor antigens gen-
erally target peptides with poor avidity. Our observations
in mice seem analogous to those observed in human mela-
noma patients in which vaccination with the gp100209–217
peptide is inefficient, unless that peptide is altered to in-
crease its avidity for the HLA-A*0201 molecule (9). Thus,
the optimization of self/tumor peptides for binding to
MHC molecules should be further explored in future can-
cer vaccine development.
One observation in mouse and in man is that therapeutic
immunization designed to treat established tumor is gener-
ally ineffective. Where immunization can induce tumor
antigen-specific T cells, the destruction of an established
tumor is not reproducibly observed. In the present model,
adoptive transfer of T cells was required in order for vac-
cine and IL-2 to reproducibly induce the destruction of tu-
mor. There apparently are quantitative or qualitative differ-
ences between cells expanded ex vivo and used for
adoptive transfer, and cells expanded in vivo as a result of
immunization. Cells induced by vaccination are likely to be
lower in number; furthermore, they may be quiescent or
refractory to activation by tumor cells, perhaps in a way
similar to the changes observed in T cells during chronic
infection (44). Thus, we seek to use, in new clinical trials,
Figure 7. Histological analysis reveals presence of V 13  T cells in tu-
mors and demonstrates the activating effects of IL-2. T cells and tissue ar-
chitecture within tumors were visualized after vaccination with or with-
out IL-2. C57BL/6 mice bearing 14-d B16 tumors received 107 pmel-1
splenocytes and vaccination with hgp10025–33 peptide in IFA and anti-
CD40 with or without IL-2. As was the case for vaccination with rVVs or
rFPVs encoding hgp100, vaccination with hgp10025–33 peptide in IFA and
anti-CD40 after the adoptive transfer of pmel-1 cells was greatly en-
hanced with the addition of IL-2 in repeated experiments (not depicted).
Tumors were excised 7 d after the vaccination and 4- m frozen sections
were stained with anti-V 13 mAb (top, arrows) or IgG control (bottom),
counterstained with hematoxylin, and photographed at an original mag-
nification of 200. (left) pmel-1 cells plus hgp100 vaccination. (right)
pmel-1 cells plus hgp100 vaccination followed by IL-2 administration.T
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the combined regimen of cells, IL-2, and vaccination with
an altered peptide ligand described in this paper.
The use of lymphodepletion (nonmyeloablative condi-
tioning) may enhance the function of adoptively transferred
T cells as shown previously (45, 46). Lymphodepletion
may facilitate immune responses by deletion of endogenous
regulatory T cells, or by increasing the availability of en-
dogenous immune activating cytokines such as IL-7 or IL-
15. Results in the clinic are encouraging, but the consistent
induction of complete responses in our patients with cancer
remains the focus of our ongoing clinical efforts. We are
now using the pmel-1 model to explore the immune-
enhancing mechanisms of nonmyeloablative conditioning.
IL-2 Enhances CD8  T Cell Function In Vivo.  IL-2 can
be clinically successful but the mechanism responsible for
the sometimes-dramatic clinical antitumor responses is un-
clear (47). We had found previously that IL-2 could aug-
ment the T cell response to a virus (38). These observa-
tions have been confirmed and expanded recently by
others (48). In the present set of experiments, IL-2 seemed
to function more as a T cell activation factor than as a
growth factor: it not only boosted specific T cell numbers
after immunization but also enhanced their ability to pro-
duce IFN-  upon infiltration into tumors. It is possible
that IL-2 increased both proliferation and death of pmel-1
T cells. We are currently investigating whether adminis-
tration of IL-2 can be replaced by the induction of a pro-
ductive CD4  T cell response, the major source of IL-2
during a typical pathogen-specific immune response, or by
other cytokines, including IL-15.
Autoimmune Consequences of Immunotherapy Targeted at the
gp100 Self Antigen.  Vitiligo, the usually incomplete de-
struction of normal tissue, was observed in most mice
where successful tumor destruction was observed (Fig. 4).
Induction of vitiligo has been correlated with tumor pro-
tection in the induction of TRP-1–specific immune re-
sponses (5, 49, 50). In humans, vitiligo has previously been
highly correlated with successful response to IL-2–based
immunotherapy in patients with metastatic malignant mel-
anoma (51).
Our observations in the pmel-1 model, and in human
patients treated with T cells (45), are that CD8  T cell acti-
vation results in the destruction of tumor cells at least as
well as normal cells. Thus, we did not find evidence of a
tumor-specific “barrier” that prevented T cell–mediated
tumor destruction while allowing destruction of normal
tissue (20). Both tumor and normal tissue were attacked
and destroyed by the treatment regimen, with the tumor
destruction generally being more complete in this model.
Conclusion.  Together, these observations have allowed
us to identify three requirements that were all strictly nec-
essary yet not individually sufficient for reversing the func-
tionally tolerant state of adoptively transferred T cells re-
sulting in strong tumor regression: (a) adoptive transfer of
tumor-specific T cells; (b) T cell stimulation through anti-
gen-specific vaccination using an altered peptide ligand
rather than the native self-peptide for vaccination; and (c)
coadministration of IL-2. When used in combination, these
requirements defined the components of successful antitu-
mor treatment. Based on these data, clinical trials that use
adoptive cell transfer used in combination with IL-2 and
vaccination with an altered peptide ligand are being initi-
ated in patients with cancer.
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